High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial | Zendy

Jessica A. Alvarez | Zendy; Jennie H. Law | Zendy; Kathryn E. Coakley | Zendy; Susu M. Zughaier | Zendy; Li Hao | Zendy; Khadijeh Shahid Salles | Zendy; Haimanot Wasse | Zendy; Orlando M. Gutiérrez | Zendy; Thomas R. Ziegler | Zendy; Vin Tangpricha | Zendy

Open Access

High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial

Author(s) -

Jessica A. Alvarez,

Jennie H. Law,

Kathryn E. Coakley,

Susu M. Zughaier,

Li Hao,

Khadijeh Shahid Salles,

Haimanot Wasse,

Orlando M. Gutiérrez,

Thomas R. Ziegler,

Vin Tangpricha

Publication year - 2012

Publication title -

american journal of clinical nutrition

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.608

H-Index - 336

eISSN - 1938-3207

pISSN - 0002-9165

DOI - 10.3945/ajcn.112.040642

Subject(s) - cholecalciferol , secondary hyperparathyroidism , medicine , parathyroid hormone , placebo , vitamin d and neurology , endocrinology , vitamin d deficiency , kidney disease , hyperparathyroidism , vitamin , blood pressure , calcium , alternative medicine , pathology

Vitamin D deficiency contributes to secondary hyperparathyroidism, which occurs early in chronic kidney disease (CKD).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research